Last week, Dr. Gail Naughton, CEO of Histrogen, Inc. a regenerative medicine company that develops solutions based on the products of *newborn fibroblasts grown under embryonic conditions, addressed attendees at the 4th Annual Stem Cell Summit in New York. Dr. Naughton presented preliminary mid-trial results from Histrogen’s first human clinical evaluation of *it’s promising breakthrough [...]
More...
More...
Comment